INSERM UMR U649, Institut de Recherche Thérapeutique 1, Université de Nantes, 8 quai Moncousu, 44007 Nantes Cedex 01, France.
Exp Eye Res. 2011 Oct;93(4):491-502. doi: 10.1016/j.exer.2011.06.012. Epub 2011 Jun 24.
Systemic delivery of recombinant adeno-associated virus (rAAV) vectors has recently been shown to cross the blood brain barrier in rodents and large animals and to efficiently target cells of the central nervous system. Such approach could be particularly interesting to treat lysosomal storage diseases or neurodegenerative disorders characterized by multiple organs injuries especially neuronal and retinal dysfunctions. However, the ability of rAAV vector to cross the blood retina barrier and to transduce retinal cells after systemic injection has not been precisely determined. In this study, gene transfer was investigated in the retina of neonatal and adult rats after intravenous injection of self-complementary (sc) rAAV serotype 1, 5, 6, 8, and 9 carrying a CMV-driven green fluorescent protein (GFP), by fluorescence fundus photography and histological examination. Neonatal rats injected with scAAV2/9 vector displayed the strongest GFP expression in the retina, within the retinal pigment epithelium (RPE) cells. Retinal tropism of scAAV2/9 vector was further assessed after systemic delivery in large animal models, i.e., dogs and cats. Interestingly, efficient gene transfer was observed in the RPE cells of these two large animal models following neonatal intravenous injection of the vector. The ability of scAAV2/9 to transduce simultaneously neurons in the central nervous system, and RPE cells in the retina, after neonatal systemic delivery, makes this approach potentially interesting for the treatment of infantile neurodegenerative diseases characterized by both neuronal and retinal damages.
系统递送重组腺相关病毒(rAAV)载体最近已被证明可以穿过啮齿动物和大动物的血脑屏障,并有效地靶向中枢神经系统的细胞。这种方法对于治疗溶酶体贮积症或神经退行性疾病特别有趣,这些疾病的特点是多个器官损伤,特别是神经元和视网膜功能障碍。然而,rAAV 载体穿过血视网膜屏障并在全身注射后转导视网膜细胞的能力尚未得到精确确定。在这项研究中,通过荧光眼底摄影和组织学检查,研究了在新生和成年大鼠的视网膜中,经静脉注射自我互补(sc)rAAV 血清型 1、5、6、8 和 9 后,携带 CMV 驱动的绿色荧光蛋白(GFP)的基因转移。注射 scAAV2/9 载体的新生大鼠在视网膜色素上皮(RPE)细胞中显示出最强的 GFP 表达。在大型动物模型(即狗和猫)中进行全身递送后,进一步评估了 scAAV2/9 载体的视网膜嗜性。有趣的是,在这两种大型动物模型中,新生静脉注射该载体后,RPE 细胞中观察到有效的基因转移。scAAV2/9 在新生儿全身递送后同时转导中枢神经系统中的神经元和视网膜中的 RPE 细胞的能力,使得这种方法对于治疗同时具有神经元和视网膜损伤的婴儿神经退行性疾病具有潜在的意义。